The enhancement of PD-1/PD-L1 and CTLA-4 expression via the EGFR pathway suggests a potent avenue for immune suppression in lung cancer, exacerbated by ERK and NF-κB pathways (26). The gene discussed is CTLA4; the disease is lung carcinoma.